Presence of mutation conferring resistance to lamivudine in plasma and cerebrospinal fluid of HIV-1-infected patients

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 21, Issue 4, 1999, Pages 277-280

  Chien, Jason W ^a   Valdez, Hernan ^a   McComsey, Grace ^a   McClernon, Daniel ^b   St Clair, Marty ^b   Lederman, Michael M ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Antiretroviral agents; Cerebrospinal fluid; Lamivudine; Mutation; Resistance

Indexed keywords

INDINAVIR; LAMIVUDINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG PENETRATION; GENE AMPLIFICATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; PRIORITY JOURNAL; RNA SEQUENCE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0033179067     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-199908010-00004     Document Type: Article

References (12)

1. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997;349:1294.
2. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997;11:F101-5.
3. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990;28:495-53.
4. Di Stefano M, Monno L, Ramon Fiore J, Angarano G. In vivo evidence of HIV productive infection in cerebrospinal fluid of patients with HIV-1 encephalopathy. AIDS 1997;11:698-9.
5. Foudraine N, de Wolf F, Hoetelmans R, et al. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998;351:1547-51.
6. Gisolf E, Colebunders R, Van Wanzeele F, et al., on behalf of the Prometheus Study Group. Treatment with ritonavir/saquinavir versus ritonavir/saquinavir/stavudine [abstract 389]. Presented at the V Conference on Retroviruses and Opportunistic Infections, Chicago, 1998.
7. Cameron DW, Japour A, Mellors J, et al. Antiretroviral safety & durability of ritonavir (RIT)-saquinavir (SQV) in protease inhibitor-naive patients in year two follow-up [abstract 388]. Presented at the V Conference on Retroviruses and Opportunistic Infections, Chicago, 1998.
8. Stahle L, Martin C, Svensson JO, Sonnerborg A. Indinavir in cerebrospinal fluid of HIV-1-infected patients. Lancet 1997;350:1823.
9. Sei S, Stewart SK, Farley M, et al. Evaluation of human immunodeficiency virus (HIV) type 1 RNA levels in cerebrospinal fluid and viral resistance to zidovudine in children with HIV encephalopathy. J Infect Dis 1996;74:1200-6.
10. Gisslen M, Norkrans G, Svennerholm B, Hagberg L. The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J Infect Dis 1997;175:434-7.
11. Cunningham P, Smith D, Satchell C, Cooper DA, Brew B. In vivo comparison of RT inhibitor resistance patterns in paired cerebrospinal fluid and blood of HIV-1 infected patients with a novel line probe assay [abstract 682]. Presented at the V Conference on Retroviruses and Opportunistic Infections, Chicago, 1998.
12. McArthur JC, McClernon DR; Cronin MF, et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997;42:689-98.